88 related articles for article (PubMed ID: 24464577)
1. Context-dependent role of Grb7 in HER2+ve and triple-negative breast cancer cell lines.
Lim RC; Price JT; Wilce JA
Breast Cancer Res Treat; 2014 Feb; 143(3):593-603. PubMed ID: 24464577
[TBL] [Abstract][Full Text] [Related]
2. GRB7 is required for triple-negative breast cancer cell invasion and survival.
Giricz O; Calvo V; Pero SC; Krag DN; Sparano JA; Kenny PA
Breast Cancer Res Treat; 2012 Jun; 133(2):607-15. PubMed ID: 22005836
[TBL] [Abstract][Full Text] [Related]
3. Epigenetically altered miR‑193a‑3p promotes HER2 positive breast cancer aggressiveness by targeting GRB7.
Tang Y; Yang S; Wang M; Liu D; Liu Y; Zhang Y; Zhang Q
Int J Mol Med; 2019 Jun; 43(6):2352-2360. PubMed ID: 31017268
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Cyclic Peptide Inhibitors of the Grb7 Breast Cancer Target: Small Change in Cargo Results in Large Change in Cellular Activity.
Sang J; Kulkarni K; Watson GM; Ma X; Craik DJ; Henriques ST; Poth AG; Benfield AH; Wilce JA
Molecules; 2019 Oct; 24(20):. PubMed ID: 31627265
[TBL] [Abstract][Full Text] [Related]
5. GRB7 protein over-expression and clinical outcome in breast cancer.
Ramsey B; Bai T; Hanlon Newell A; Troxell M; Park B; Olson S; Keenan E; Luoh SW
Breast Cancer Res Treat; 2011 Jun; 127(3):659-69. PubMed ID: 20635137
[TBL] [Abstract][Full Text] [Related]
6. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
7. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.
Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ
Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801
[TBL] [Abstract][Full Text] [Related]
8. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
[TBL] [Abstract][Full Text] [Related]
9. GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma.
Bivin WW; Yergiyev O; Bunker ML; Silverman JF; Krishnamurti U
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):553-558. PubMed ID: 26945445
[TBL] [Abstract][Full Text] [Related]
10. GRB7 dependent proliferation of basal-like, HER-2 positive human breast cancer cell lines is mediated in part by HER-1 signaling.
Luoh SW; Wagoner W; Wang X; Hu Z; Lai X; Chin K; Sears R; Ramsey E
Mol Carcinog; 2019 May; 58(5):699-707. PubMed ID: 30604896
[TBL] [Abstract][Full Text] [Related]
11. Expression of estrogen and progesterone receptors and estrogen metabolizing enzymes in different breast cancer cell lines.
Hevir N; Trošt N; Debeljak N; Rižner TL
Chem Biol Interact; 2011 May; 191(1-3):206-16. PubMed ID: 21182832
[TBL] [Abstract][Full Text] [Related]
12. Expression levels of HER2/neu and those of collocated genes at 17q12-21, in breast cancer.
Glynn RW; Miller N; Mahon S; Kerin MJ
Oncol Rep; 2012 Jul; 28(1):365-9. PubMed ID: 22552811
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a bioluminescent MDA-MB-231 cell line for human triple-negative breast cancer research.
Wang K; Xie S; Ren Y; Xia H; Zhang X; He J
Oncol Rep; 2012 Jun; 27(6):1981-9. PubMed ID: 22446691
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
16. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
17. An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer.
McCleland ML; Adler AS; Shang Y; Hunsaker T; Truong T; Peterson D; Torres E; Li L; Haley B; Stephan JP; Belvin M; Hatzivassiliou G; Blackwood EM; Corson L; Evangelista M; Zha J; Firestein R
Cancer Res; 2012 Nov; 72(22):5812-23. PubMed ID: 23139210
[TBL] [Abstract][Full Text] [Related]
18. Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer.
Sparano JA; Goldstein LJ; Childs BH; Shak S; Brassard D; Badve S; Baehner FL; Bugarini R; Rowley S; Perez EA; Shulman LN; Martino S; Davidson NE; Kenny PA; Sledge GW; Gray R
Clin Cancer Res; 2011 Nov; 17(22):7194-203. PubMed ID: 21933890
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
20. Coexpression of Grb7 with epidermal growth factor receptor or Her2/erbB2 in human advanced esophageal carcinoma.
Tanaka S; Mori M; Akiyoshi T; Tanaka Y; Mafune K; Wands JR; Sugimachi K
Cancer Res; 1997 Jan; 57(1):28-31. PubMed ID: 8988034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
